Latest chemotherapy Stories
SAN DIEGO, May 5, 2014 /PRNewswire/ -- MEI Pharma, Inc.
New Data Include Results on Oncotype DX's Prognosis of Late Recurrence in Invasive Breast Cancer and Clinical Utility in Ductal Carcinoma In Situ (DCIS) REDWOOD CITY, Calif., May 5, 2014 /PRNewswire/
A team of Italian doctors say women, people with epithelial mesothelioma, and those who have chemotherapy before surgery will reap the most benefit from lung-removing surgery. Raleigh,
NEW YORK, May 1, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that the data from its multi-institutional
Blair, Ph.D., testifies how God enabled him to live cancer-free, without treatment MAITLAND, Fla., April 29, 2014 /PRNewswire-iReach/ -- In his new book,
Austin-based tech company, Photetica, is now in the clinical trial phase with its newest medical device, Lazarus, and has launched a crowdfunding campaign through Indiegogo to support clinical
HACKENSACK, N.J., April 28, 2014 /PRNewswire/ -- Results from a study published in Clinical Cancer Research demonstrate that oncologists were able to accurately predict which therapies
BOCA RATON, Fla., April 28, 2014 /PRNewswire/ -- TransMedia Group (www.transmediagroup.com) said it will
The American Society for Radiation Oncology (ASTRO) has issued a new guideline, “The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline,” that details the use of adjuvant radiation therapy in the treatment of endometrial cancer.
Intravenous therapy, commonly known as IV therapy, is known as the administration of a liquid substance directly into a vein. It is also known as drip therapy, because most often the liquid is suspended above the IV site by an infusion pump, and runs through a drip chamber, which prevents air from entering the line. IVs are the preferred method of drug administration in hospital settings because they are the fastest known route of getting medication to the body. Intravenous therapy can also...
Antiviral Chemistry & Chemotherapy is a peer-reviewed academic journal published bi-monthly by International Medical Press in London since 1997. When founded in January 1990, it was published by Blackwell Science. The current editor-in-chief is Hugh J. Field of University of Cambridge, UK. The journal publishes primary papers and reviews on all aspects of the preclinical development of antiviral agents, including their chemical synthesis, biochemistry, pharmacology, mode of action and...
- totally perplexed and mixed up.